Ares Management Upsizes Tempus Debt Facilities to $560 Million
Ares Management (NYSE: ARES) has expanded its debt financing for Tempus AI (NASDAQ: TEM) with an additional $300 million, bringing the total debt package to $560 million. The new financing supports Tempus' recent acquisition of Ambry Genetics, which closed on February 3, 2025.
Tempus, founded in 2015, specializes in implementing AI solutions in healthcare, focusing on clinical care and research products. The company's integrated business model includes patient sequencing, data collection through licensing and analytical tools, and diagnostic testing insights across oncology, cardiology, pathology, and radiology.
This financing demonstrates Ares' capability to provide scalable capital to both non-sponsor-backed and sponsor-backed borrowers, with Ares expressing confidence in Tempus' growth strategy and the strategic acquisition of Ambry.
Ares Management (NYSE: ARES) ha ampliato il suo finanziamento per Tempus AI (NASDAQ: TEM) con un ulteriore importo di 300 milioni di dollari, portando il totale del pacchetto di debito a 560 milioni di dollari. Il nuovo finanziamento sostiene l'acquisizione recente di Ambry Genetics da parte di Tempus, conclusa il 3 febbraio 2025.
Tempus, fondata nel 2015, si specializza nell'implementazione di soluzioni di intelligenza artificiale nel settore sanitario, con un focus sui prodotti per la cura clinica e la ricerca. Il modello di business integrato dell'azienda include il sequenziamento dei pazienti, la raccolta di dati tramite licenze e strumenti analitici, e approfondimenti sui test diagnostici in oncologia, cardiologia, patologia e radiologia.
Questo finanziamento dimostra la capacità di Ares di fornire capitale scalabile a prestatari sia senza sponsor che sostenuti da sponsor, con Ares che esprime fiducia nella strategia di crescita di Tempus e nell'acquisizione strategica di Ambry.
Ares Management (NYSE: ARES) ha ampliado su financiamiento para Tempus AI (NASDAQ: TEM) con un adicional de 300 millones de dólares, llevando el total del paquete de deuda a 560 millones de dólares. El nuevo financiamiento apoya la reciente adquisición de Ambry Genetics por parte de Tempus, que se cerró el 3 de febrero de 2025.
Tempus, fundada en 2015, se especializa en implementar soluciones de IA en la atención médica, enfocándose en productos de atención clínica e investigación. El modelo de negocio integrado de la empresa incluye secuenciación de pacientes, recolección de datos a través de licencias y herramientas analíticas, y conocimientos de pruebas diagnósticas en oncología, cardiología, patología y radiología.
Este financiamiento demuestra la capacidad de Ares para proporcionar capital escalable tanto a prestatarios sin respaldo de patrocinador como a aquellos respaldados por patrocinadores, con Ares expresando confianza en la estrategia de crecimiento de Tempus y en la adquisición estratégica de Ambry.
Ares Management (NYSE: ARES)는 Tempus AI (NASDAQ: TEM)의 부채 금융을 추가로 3억 달러 확대하여 총 부채 패키지를 5억 6천만 달러로 늘렸습니다. 이 새로운 금융은 Tempus가 2025년 2월 3일에 마감한 Ambry Genetics의 최근 인수를 지원합니다.
2015년에 설립된 Tempus는 임상 치료 및 연구 제품에 중점을 두고 의료 분야에 AI 솔루션을 구현하는 데 전문화되어 있습니다. 이 회사의 통합 비즈니스 모델에는 환자 시퀀싱, 라이센스를 통한 데이터 수집 및 분석 도구, 그리고 종양학, 심장학, 병리학, 방사선학 전반에 걸친 진단 테스트 통찰력이 포함됩니다.
이 금융은 Ares가 후원자가 없는 차입자와 후원자가 있는 차입자 모두에게 확장 가능한 자본을 제공할 수 있는 능력을 보여주며, Ares는 Tempus의 성장 전략과 Ambry의 전략적 인수에 대한 신뢰를 표현하고 있습니다.
Ares Management (NYSE: ARES) a élargi son financement de dette pour Tempus AI (NASDAQ: TEM) avec un montant additionnel de 300 millions de dollars, portant le total du paquet de dettes à 560 millions de dollars. Ce nouveau financement soutient l'acquisition récente d'Ambry Genetics par Tempus, qui a été finalisée le 3 février 2025.
Fondée en 2015, Tempus se spécialise dans l'implémentation de solutions d'IA dans le secteur de la santé, en se concentrant sur les soins cliniques et les produits de recherche. Le modèle commercial intégré de l'entreprise comprend le séquençage des patients, la collecte de données via des licences et des outils analytiques, ainsi que des informations sur les tests diagnostiques dans les domaines de l'oncologie, de la cardiologie, de la pathologie et de la radiologie.
Ce financement démontre la capacité d'Ares à fournir un capital évolutif à la fois pour les emprunteurs sans sponsor et ceux soutenus par un sponsor, Ares exprimant sa confiance dans la stratégie de croissance de Tempus et l'acquisition stratégique d'Ambry.
Ares Management (NYSE: ARES) hat die Kreditfinanzierung für Tempus AI (NASDAQ: TEM) um weitere 300 Millionen US-Dollar erhöht und damit das gesamte Schuldenpaket auf 560 Millionen US-Dollar gebracht. Die neue Finanzierung unterstützt die kürzliche Übernahme von Ambry Genetics durch Tempus, die am 3. Februar 2025 abgeschlossen wurde.
Tempus, gegründet im Jahr 2015, hat sich auf die Implementierung von KI-Lösungen im Gesundheitswesen spezialisiert, mit einem Fokus auf klinische Pflege und Forschungsprodukte. Das integrierte Geschäftsmodell des Unternehmens umfasst die Sequenzierung von Patienten, die Datensammlung durch Lizenzen und analytische Werkzeuge sowie diagnostische Testeinblicke in Onkologie, Kardiologie, Pathologie und Radiologie.
Diese Finanzierung zeigt Ares' Fähigkeit, skalierbares Kapital sowohl für nicht gesponserte als auch für gesponserte Kreditnehmer bereitzustellen, wobei Ares Vertrauen in die Wachstumsstrategie von Tempus und die strategische Übernahme von Ambry ausdrückt.
- Increased debt facility by $300 million, reaching total package of $560 million
- Successfully closed acquisition of Ambry Genetics, expanding market presence
- Demonstrated ability to secure significant institutional funding
- Increased debt burden could impact financial flexibility
- Higher interest expenses from expanded debt facilities
Insights
This
The financing structure offers several key advantages: First, the staged investment approach (
The Ambry Genetics acquisition is particularly noteworthy as it expands Tempus' capabilities across the precision medicine value chain:
- Enhanced diagnostic testing capabilities through Ambry's established infrastructure
- Expanded data collection opportunities for AI model training
- Strengthened position in oncology and cardiology markets
For Ares shareholders, this transaction showcases the firm's ability to identify and finance transformative healthcare deals, particularly in the rapidly growing AI-enabled healthcare sector. The deal structure also highlights Ares' competitive advantage in providing large-scale, flexible financing to non-sponsor-backed companies - a relatively underserved market segment with potentially higher yields.
Founded in 2015, Tempus is bringing data and AI to healthcare businesses through innovative technology solutions focused on clinical care and research products. With an integrated business model of sequencing patients through therapy and trial matching, collecting data through licensing and analytical tools, and providing insights to further enhance their diagnostic testing, Tempus is committed to helping physicians and researchers advance efforts in oncology, cardiology, pathology and radiology.
“We are pleased to upsize our investment in Tempus, underscoring Ares’ ability to provide flexible capital at scale to both non-sponsor-backed and sponsor-backed borrowers,” said Douglas Dieter, Dr.P.H., Partner in the Ares Credit Group. “Over the last two years, we’ve been impressed by the Tempus team’s execution of its growth strategy and complementary acquisition of Ambry, and we look forward to further supporting their efforts in AI-enabled solutions that help advancements in medicine.”
“We appreciate this latest investment from Ares, which supports Tempus’ acquisition of Ambry and our commitment to deliver technological innovation that can help healthcare providers improve patient outcomes,” said Jim Rogers, Chief Financial Officer of Tempus.
About Ares Management Corporation
Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of December 31, 2024, Ares Management Corporation's global platform had over
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218703564/en/
Ares
Jacob Silber, +1-212-301-0376
media@aresmgmt.com
Tempus
Erin Carron
Erin.carron@tempus.com
Source: Ares Management Corporation
FAQ
What is the total value of Ares Management's debt facilities for Tempus as of 2025?
When did Tempus complete the Ambry Genetics acquisition?
How much additional debt financing did ARES provide to Tempus in 2025?
What is the purpose of Tempus' new debt financing from ARES?
How much did ARES previously provide in debt financing to Tempus in 2022-2023?
